Generic Injectables Market Size, Growth, Analysis, Outlook, Forecast 2024-2032

(MENAFN- IMARC Group) The latest report published by IMARC Group, titled“ Generic Injectables Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032 ”, offers a comprehensive analysis of the industry, which comprises insights on
generic injectables market
. The report also includes competitor and regional analysis, and contemporary advancements in the global market.

The global generic injectables market size reached US$ 47.5 Billion in 2023. Looking forward,
IMARC Group expects the market to reach US$ 90.9 Billion by 2032, exhibiting a growth rate (CAGR) of 7.2% during 2024-2032.

Get a Sample Copy of this Report:

Factors Affecting the Growth of the Generic Injectables Industry:

  • Cost-Effectiveness of Injectables:

A primary factor driving the global generic injectables market is the cost-effectiveness of generic drugs compared to their branded counterparts. Generic injectables offer a more affordable alternative for healthcare systems and patients, particularly in treating chronic conditions and in markets with high price sensitivity. The lower price point is due to reduced research and development costs, as generic manufacturers do not bear the initial expenses of developing new drugs. This affordability not only improves patient access to essential medications but also reduces the financial burden on healthcare systems, making generic injectables a preferred choice in both developed and emerging markets.

  • Increasing Patent Expirations:

The rise in the global generic injectables market is significantly fueled by the expiration of patents for several blockbuster drugs. When patents expire, it opens the door for generic manufacturers to produce bioequivalent versions, often leading to a sharp increase in market competition and a corresponding decrease in prices. This transition plays a crucial role in the healthcare sector, as it facilitates the availability of essential drugs at a lower cost. In addition, the patent cliff, particularly in the biologics segment is prompting a robust growth in the biosimilars market, further expanding the scope and reach of generic injectables globally.

  • Growing Prevalence of Chronic Diseases:

The escalating prevalence of chronic diseases worldwide is a critical driver for the generic injectables market. Chronic conditions such as diabetes, cardiovascular diseases, and various cancers require ongoing treatment, often necessitating the use of injectable drugs for effective management. In addition, the growing patient pool for these diseases creates a sustained demand for affordable treatment options, thus bolstering the market for generic injectables. Moreover, the aging global population, more prone to chronic illnesses, further amplifies this demand, making generic injectables an essential component in global healthcare management. This trend underscores the importance of generic injectables in providing cost-effective, long-term treatments for chronic health conditions.

Competitive Landscape:

The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.

  • Hospira (Pfizer)
  • Fresenius Kabi
  • Hikma
  • Sandoz (Novartis)
  • Sagent
  • Sanofi
  • Baxter

Generic Injectables Market Report Segmentation:

Breakup by Therapeutic Area:

  • Oncology
  • Anaesthesia
  • Anti-infectives
  • Parenteral Nutrition
  • Cardiovascular

Oncology represents the largest segment due to the rising global incidence of various types of cancers, necessitating an increased demand for oncology drugs, many of which are administered via injectables for effective treatment.

Breakup by Container:

  • Vials
  • Ampoules
  • Premix
  • Prefilled Syringes

Vials are the most commonly used container for generic injectables due to their cost-effectiveness, ease of handling, and suitability for a wide range of liquid drug formulations, making them a practical choice for healthcare providers.

Breakup by Distribution Channel:

  • Hospitals
  • Retail Pharmacy

Hospitals are the primary distribution channel for generic injectables due to the immediate requirement and administration of these drugs in a controlled healthcare setting, particularly for acute care and chronic disease management.

Breakup by Region:

  • North America (United States, Canada)
  • Europe (Germany, France, United Kingdom, Italy, Spain, Others)
  • Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)
  • Latin America (Brazil, Mexico, Others)
  • Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Other)

North America leads in the generic injectables market due to its advanced healthcare infrastructure, high healthcare spending, stringent regulatory policies ensuring drug quality, and the presence of key pharmaceutical players in this region.

Global Generic Injectables Market Trends:

The increasing focus on complex injectables, such as high-potency active pharmaceutical ingredients (HPAPIs) and long-acting formulations is favoring the market. These complex products offer higher margins for manufacturers and are less likely to face intense competition, unlike standard generics. Additionally, there's a growing emphasis on oncology injectables, driven by a rise in cancer incidence globally. This trend is leading to a surge in demand for chemotherapy and supportive care drugs in injectable form.

Furthermore, advancements in drug delivery technologies are enhancing the stability and efficacy of generic injectables, making them more appealing to both healthcare providers and patients. These trends, combined with regulatory support for generic drug approvals, particularly in high-burden healthcare markets, are further propelling the growth of the market.

Key highlights of the report:

  • Market Performance (2018-2023)
  • Market Outlook (2024-2032)
  • Porter's Five Forces Analysis
  • Market Drivers and Success Factors
  • SWOT Analysis
  • Value Chain
  • Comprehensive Mapping of the Competitive Landscape

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.

Contact US:
134 N 4th St. Brooklyn, NY 11249, USA
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.